Skip to main content
. 2017 Jun 21;174(15):2457–2470. doi: 10.1111/bph.13855

Figure 7.

Figure 7

Bouchardatine ameliorates HF‐induced lipid accumulation and activates the LKB1–AMPK pathway in the liver. Liver TG levels and phosphorylated levels of LKB1–AMPK–ACC were measured after Bou treatment. (A) TG levels. (B) NAD+/NADH ratio. (C) SIRT1 activity. (D, E) ATP levels and AMP/ATP ratio. (F) Expression of LKB1–AMPK signalling pathway. * P < 0.05, compared with CH group; # P < 0.05 compared with HF group (n = 8 mice in each group).